Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Longevity market projected to hit $67 billion by 2035

Research by SNS Insider projects the global longevity market will grow from USD 27.61 billion in 2025 to USD 67.03 billion by 2035, reflecting a 9.41% compound annual growth rate (CAGR) from 2026 to 2035. The U.S. market is expected to expand significantly, reaching USD 20.17 billion in 2035, up from USD 9.16 billion in 2025, with an 8.34% CAGR. This growth is primarily driven by the increasing prevalence of age-related diseases, heightened interest in preventive healthcare, and the rising demand for nutraceuticals and anti-aging therapeutics. Technological advancements in regenerative medicine, AI-enabled drug discovery, and biomarker technologies are also contributing to this upward trend.

The report highlights that in 2025, nutraceuticals and dietary supplements will dominate the product landscape, capturing 28.05% of the market share. Notably, senolytics and senotherapeutics are anticipated to experience the fastest growth rates, signaling a shift towards targeted therapies that address cellular aging. In terms of technology, genomics and epigenetics are expected to lead the market, while biomarker technologies—including aging clocks—are poised for rapid expansion. The preventive healthcare and wellness segment is projected to remain the largest application area, with individuals being the primary end-users and direct-to-consumer channels leading distribution.

This data underscores a critical shift in the longevity sector, emphasizing the importance of preventive strategies and personalized medicine. As the market evolves, researchers and biotech professionals must adapt their focus towards developing innovative solutions that align with these trends, particularly in the realms of senolytics and biomarker technologies. This strategic pivot could significantly influence drug development timelines and research priorities in aging biology, fostering a more proactive approach to healthspan extension.

Source: longevity.technology